Pharmacokinetics and relative bioavailability of an oral amoxicillin-apramycin combination in pigs

Chongshan Dai, Tingting Zhao, Xing Yang, Xilong Xiao, Tony Velkov, Shusheng Tang

Research output: Contribution to journalArticleResearchpeer-review

Abstract

A new compound granular premix of amoxicillin (20% w/w dry mass)/apramycin (5% w/w dry mass) was developed, and its pharmacokinetics and relative bioavailability were determined in pigs following oral administration following a cross-over study design. The pharmacokinetic parameters of amoxicillin (t1/2λ = 6.43 ± 4.85h, Cmax= 3.2 ± 1.35 μg mL-1, Tmax = 1.92 ± 0.58, AUCINF = 8.98 ± 2.11 h μg mL-1) and apramycin (t1/2λ = 8.67±4.4h, Cmax= 0.23 ± 0.12 μg mL-1, Tmax = 2.25 ± 0.82 h, AUCINF = 12.37 ± 8.64h μg mL-1) when administered as the amoxicillin-apramycin granular premix did not significantly differ from those for the single-ingredient powder form of each component. The relative bioavailability of amoxicillin following oral administration of the amoxicillin-apramycin granular premix was 22.62% when compared to the intramuscular administration of commercial amoxicillin sodium-powder. This is the first report of a new amoxicillin-apramycin combination which has a potential veterinary application the for prevention and treatment digestive tract infections in pigs.

Original languageEnglish
Article numbere0176149
Number of pages12
JournalPLoS ONE
Volume12
Issue number4
DOIs
Publication statusPublished - 1 Apr 2017

Cite this

Dai, Chongshan ; Zhao, Tingting ; Yang, Xing ; Xiao, Xilong ; Velkov, Tony ; Tang, Shusheng. / Pharmacokinetics and relative bioavailability of an oral amoxicillin-apramycin combination in pigs. In: PLoS ONE. 2017 ; Vol. 12, No. 4.
@article{366a2e6701e9404faceb464b1b5e07ec,
title = "Pharmacokinetics and relative bioavailability of an oral amoxicillin-apramycin combination in pigs",
abstract = "A new compound granular premix of amoxicillin (20{\%} w/w dry mass)/apramycin (5{\%} w/w dry mass) was developed, and its pharmacokinetics and relative bioavailability were determined in pigs following oral administration following a cross-over study design. The pharmacokinetic parameters of amoxicillin (t1/2λ = 6.43 ± 4.85h, Cmax= 3.2 ± 1.35 μg mL-1, Tmax = 1.92 ± 0.58, AUCINF = 8.98 ± 2.11 h μg mL-1) and apramycin (t1/2λ = 8.67±4.4h, Cmax= 0.23 ± 0.12 μg mL-1, Tmax = 2.25 ± 0.82 h, AUCINF = 12.37 ± 8.64h μg mL-1) when administered as the amoxicillin-apramycin granular premix did not significantly differ from those for the single-ingredient powder form of each component. The relative bioavailability of amoxicillin following oral administration of the amoxicillin-apramycin granular premix was 22.62{\%} when compared to the intramuscular administration of commercial amoxicillin sodium-powder. This is the first report of a new amoxicillin-apramycin combination which has a potential veterinary application the for prevention and treatment digestive tract infections in pigs.",
author = "Chongshan Dai and Tingting Zhao and Xing Yang and Xilong Xiao and Tony Velkov and Shusheng Tang",
year = "2017",
month = "4",
day = "1",
doi = "10.1371/journal.pone.0176149",
language = "English",
volume = "12",
journal = "PLoS ONE",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "4",

}

Pharmacokinetics and relative bioavailability of an oral amoxicillin-apramycin combination in pigs. / Dai, Chongshan; Zhao, Tingting; Yang, Xing; Xiao, Xilong; Velkov, Tony; Tang, Shusheng.

In: PLoS ONE, Vol. 12, No. 4, e0176149, 01.04.2017.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Pharmacokinetics and relative bioavailability of an oral amoxicillin-apramycin combination in pigs

AU - Dai, Chongshan

AU - Zhao, Tingting

AU - Yang, Xing

AU - Xiao, Xilong

AU - Velkov, Tony

AU - Tang, Shusheng

PY - 2017/4/1

Y1 - 2017/4/1

N2 - A new compound granular premix of amoxicillin (20% w/w dry mass)/apramycin (5% w/w dry mass) was developed, and its pharmacokinetics and relative bioavailability were determined in pigs following oral administration following a cross-over study design. The pharmacokinetic parameters of amoxicillin (t1/2λ = 6.43 ± 4.85h, Cmax= 3.2 ± 1.35 μg mL-1, Tmax = 1.92 ± 0.58, AUCINF = 8.98 ± 2.11 h μg mL-1) and apramycin (t1/2λ = 8.67±4.4h, Cmax= 0.23 ± 0.12 μg mL-1, Tmax = 2.25 ± 0.82 h, AUCINF = 12.37 ± 8.64h μg mL-1) when administered as the amoxicillin-apramycin granular premix did not significantly differ from those for the single-ingredient powder form of each component. The relative bioavailability of amoxicillin following oral administration of the amoxicillin-apramycin granular premix was 22.62% when compared to the intramuscular administration of commercial amoxicillin sodium-powder. This is the first report of a new amoxicillin-apramycin combination which has a potential veterinary application the for prevention and treatment digestive tract infections in pigs.

AB - A new compound granular premix of amoxicillin (20% w/w dry mass)/apramycin (5% w/w dry mass) was developed, and its pharmacokinetics and relative bioavailability were determined in pigs following oral administration following a cross-over study design. The pharmacokinetic parameters of amoxicillin (t1/2λ = 6.43 ± 4.85h, Cmax= 3.2 ± 1.35 μg mL-1, Tmax = 1.92 ± 0.58, AUCINF = 8.98 ± 2.11 h μg mL-1) and apramycin (t1/2λ = 8.67±4.4h, Cmax= 0.23 ± 0.12 μg mL-1, Tmax = 2.25 ± 0.82 h, AUCINF = 12.37 ± 8.64h μg mL-1) when administered as the amoxicillin-apramycin granular premix did not significantly differ from those for the single-ingredient powder form of each component. The relative bioavailability of amoxicillin following oral administration of the amoxicillin-apramycin granular premix was 22.62% when compared to the intramuscular administration of commercial amoxicillin sodium-powder. This is the first report of a new amoxicillin-apramycin combination which has a potential veterinary application the for prevention and treatment digestive tract infections in pigs.

UR - http://www.scopus.com/inward/record.url?scp=85018469364&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0176149

DO - 10.1371/journal.pone.0176149

M3 - Article

VL - 12

JO - PLoS ONE

JF - PLoS ONE

SN - 1932-6203

IS - 4

M1 - e0176149

ER -